Mark Chalmers, PhD
Principal, EU Lead
Dr. Chalmers brings a wealth of pricing, market access, and value demonstration experience with clients throughout Europe and North America. While he has working knowledge of all global Pricing & Market Access and Value Demonstration issues, he particularly excels at pricing and market access strategy, value message / story development, and payer negotiation strategy in Europe.
Dr. Chalmers has worked with clients in the pharmaceutical and biotech industries for over 10 years to address critical commercial strategic issues, including therapeutic area and market assessments, clinical trial design optimization, value proposition and message development, pricing, reimbursement, market access strategies, contracting strategies, and lifecycle management.
Do Cutting-Edge One-Time Treatments Need Equally Innovative Outcomes or Annuity Based Payment Models?
17 August 2018
CAR-T Combos: Potentially the Next Big Thing in Solid Tumors, Yet Pricing ‘Sticker Shock’ is not the Only Hurdle to be Overcome
5 March 2018
STRIMVELIS™ – The Proof Is In The Messaging
6 November 2017
The New AIFA Algorithm For Assessing ‘Innovativeness’ Of New Products In Italy: So What?
18 August 2017